MiR-372-3p inhibits the growth and metastasis of osteosarcoma cells by targeting FXYD6.

OBJECTIVE: Growing evidence has suggested that dysregulation of miR-372-3p may contribute to tumor development and progression in various tumors. However, the function of miR-372-3p in osteosarcoma has not been investigated. In the present study, we aimed to study the effects of miR-372-3p on osteosarcoma cell proliferation and metastasis and its regulation on FXYD6.
MATERIALS AND METHODS: The expression levels of miR-372-3p and FXYD6 mRNA were quantified by RT-PCR in human osteosarcoma cell lines and tissues. The effects of miR-372-3p up-regulation on osteosarcoma cell proliferation and metastasis were assessed by MTT, wound healing assay and transwell assay. Finally, the potential regulatory effect of miR-372-3p on FXYD6 expression was confirmed.
RESULTS: Our data showed that miR-372-3p was downregulated in osteosarcoma tissues compared with matched normal tissues, and the expression level of miR-372-3p was significantly lower in osteosarcoma cell lines in comparison with the normal human osteoblastic cell line. Transfection with the miR-372-3p mimic enhanced the osteosarcoma proliferation and metastasis. In vivo assay indicated that forced expression of miR-372-3p significantly suppressed tumor growth. Then, Bioinformatics prediction and experimental validation results confirmed that the function of miR-372-3p was achieved by targeting FXYD6 expression.
CONCLUSIONS: Our findings revealed that miR-372-3p served as a tumor suppressor gene by targeting FXYD6 in osteosarcoma. Thus, miR-372-3 might be a potential therapeutic method for osteosarcoma.